Patents by Inventor Kaori Kubo

Kaori Kubo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11941991
    Abstract: According to one embodiment, a platooning operation system organizes a platoon by making a plurality of vehicles cooperate. The platooning operation system includes an application acceptance processor and a platoon organization processor. The application acceptance processor accepts an application of a vehicle for admission to the platoon. The platoon organization processor which selects a platoon to which the vehicle is to be admitted or determines possibility of admission of the vehicle to the platoon, based on at least one of information on a driver driving the vehicle and information on the vehicle.
    Type: Grant
    Filed: September 8, 2020
    Date of Patent: March 26, 2024
    Assignee: TOSHIBA DIGITAL SOLUTIONS CORPORATION
    Inventors: Megumi Kobayashi, Yasuto Hatafuku, Hideki Kubo, Motokazu Iwasaki, Yoko Ikeda, Shinsuke Iuchi, Kiyoshi Takemoto, Kaori Kitami, Keishi Higashi, Tatsuki Shiraishi, Michiyo Sato, Masaru Watabiki
  • Patent number: 11628899
    Abstract: A straddled vehicle, including a cross member connecting right and left seat frames, a seat above the cross member and right and left seat frames, left and right side covers, a rear fender, an intake passage formed below the seat, between the left and right side covers and above the rear fender, an air cleaner located in a front part of the intake passage, left and right inlet ports located in a rear part of the intake passage, first and second fastening portions respectively fastening the right and left side cover to the right and left seat frames or to the rear fender. In a rear view of the vehicle, the cross member is convex upward and does not overlap the right or left inlet port, and the first and second fastening portions are located outside the intake passage, or are located inside the intake passage but does not overlap the right or left inlet port.
    Type: Grant
    Filed: February 2, 2021
    Date of Patent: April 18, 2023
    Assignee: YAMAHA HATSUDOKI KABUSHIKI KAISHA
    Inventors: Satoru Akimoto, Shidehiko Miyashiro, Toshiyuki Shirai, Yuya Ozaki, Kaori Kubo
  • Publication number: 20210245826
    Abstract: A straddled vehicle, including a cross member connecting right and left seat frames, a seat above the cross member and right and left seat frames, left and right side covers, a rear fender, an intake passage formed below the seat, between the left and right side covers and above the rear fender, an air cleaner located in a front part of the intake passage, left and right inlet ports located in a rear part of the intake passage, first and second fastening portions respectively fastening the right and left side cover to the right and left seat frames or to the rear fender. In a rear view of the vehicle, the cross member is convex upward and does not overlap the right or left inlet port, and the first and second fastening portions are located outside the intake passage, or are located inside the intake passage but does not overlap the right or left inlet port.
    Type: Application
    Filed: February 2, 2021
    Publication date: August 12, 2021
    Inventors: Satoru AKIMOTO, Shidehiko MIYASHIRO, Toshiyuki SHIRAI, Yuya OZAKI, Kaori KUBO
  • Patent number: 9585889
    Abstract: On the basis of a cathepsin S inhibitory effect, an excellent agent for treating or preventing autoimmune disease, allergic disease, graft rejection of an organ, bone marrow or tissue, systemic lupus erythematosus, or the like is provided. It was found that a nitrogen-containing bicyclic heterocyclic compound has an excellent cathepsin S inhibitory effect, thereby completing the invention. The compound of the present invention has an cathepsin S inhibitory effect, and can be used as an agent for preventing and/or treating autoimmune disease, allergic disease, graft rejection of an organ, bone marrow or tissue, systemic lupus erythematosus, or the like.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: March 7, 2017
    Assignee: Astellas Pharma Inc.
    Inventors: Yutaka Nakajima, Sunao Imada, Yuji Takasuna, Naohiro Aoyama, Takahiro Nigawara, Shohei Shirakami, Fumiyuki Shirai, Junji Sato, Keita Nakanishi, Kaori Kubo
  • Publication number: 20160228442
    Abstract: On the basis of a cathepsin S inhibitory effect, an excellent agent for treating or preventing autoimmune disease, allergic disease, graft rejection of an organ, bone marrow or tissue, systemic lupus erythematosus, or the like is provided. It was found that a nitrogen-containing bicyclic heterocyclic compound has an excellent cathepsin S inhibitory effect, thereby completing the invention. The compound of the present invention has an cathepsin S inhibitory effect, and can be used as an agent for preventing and/or treating autoimmune disease, allergic disease, graft rejection of an organ, bone marrow or tissue, systemic lupus erythematosus, or the like.
    Type: Application
    Filed: February 8, 2016
    Publication date: August 11, 2016
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Yutaka Nakajima, Sunao Imada, Yuji Takasuna, Naohiro Aoyama, Takahiro Nigawara, Shohei Shirakami, Fumiyuki Shirai, Junji Sato, Keita Nakanishi, Kaori Kubo
  • Patent number: 9328118
    Abstract: [Problem] On the basis of a cathepsin S inhibitory effect, an excellent agent for treating or preventing autoimmune disease, allergic disease, graft rejection of an organ, bone marrow or tissue, systemic lupus erythematosus, or the like is provided. [Means for Solution] It was found that a nitrogen-containing bicyclic heterocyclic compound has the excellent cathepsin S inhibitory effect, thereby completing the invention. The compound of the present invention has the cathepsin S inhibitory effect, and can be used as an agent for preventing and/or treating autoimmune disease, allergic disease, graft rejection of an organ, bone marrow or tissue, systemic lupus erythematosus, or the like.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: May 3, 2016
    Assignee: Astellas Pharma Inc.
    Inventors: Yutaka Nakajima, Sunao Imada, Yuji Takasuna, Naohiro Aoyama, Takahiro Nigawara, Shohei Shirakami, Fumiyuki Shirai, Junji Sato, Keita Nakanishi, Kaori Kubo
  • Publication number: 20150126488
    Abstract: [Problem] On the basis of a cathepsin S inhibitory effect, an excellent agent for treating or preventing autoimmune disease, allergic disease, graft rejection of an organ, bone marrow or tissue, systemic lupus erythematosus, or the like is provided. [Means for Solution] It was found that a nitrogen-containing bicyclic heterocyclic compound has the excellent cathepsin S inhibitory effect, thereby completing the invention. The compound of the present invention has the cathepsin S inhibitory effect, and can be used as an agent for preventing and/or treating autoimmune disease, allergic disease, graft rejection of an organ, bone marrow or tissue, systemic lupus erythematosus, or the like.
    Type: Application
    Filed: April 17, 2013
    Publication date: May 7, 2015
    Applicant: ASTELLAS PHARMA INC
    Inventors: Yutaka Nakajima, Sunao Imada, Yuji Takasuna, Naohiro Aoyama, Takahiro Nigawara, Shohei Shirakami, Fumiyuki Shirai, Junji Sato, Keita Nakanishi, Kaori Kubo